IRON (Disc Medicine) Debt-to-Asset : 0.08 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRON Disc Medicine Inc IRON
35 GF Score
Price $68.49
! 3 Warning Signs
View Full Analysis

What is Disc Medicine Debt-to-Asset?

Disc Medicine IRON -1.50% 35 Debt-to-Asset is 0.08 as of Jun. 2026. GuruFocus rates IRON with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Disc Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.32 Mil. Disc Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $60.55 Mil. Disc Medicine's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $735.07 Mil. Disc Medicine's debt to asset for the quarter that ended in Jun. 2026 was 0.08.

Disc Medicine  (NAS:IRON) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Disc Medicine Debt-to-Asset Related Terms

Disc Medicine Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Disc Medicine's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Disc Medicine Debt-to-Asset Chart

Disc Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.02 0.01 0.01 0.06 0.04

Disc Medicine Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.04 0.04 0.08

IRON vs CLDX, NAMS, MBX: Debt-to-Asset Comparison

For the Biotechnology subindustry, Disc Medicine's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Disc Medicine Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Disc Medicine's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Disc Medicine's Debt-to-Asset falls into.


IRON
35GF Score
Disc Medicine Inc IRON
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Disc Medicine Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Disc Medicine's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.611 + 30.412) / 806.879
=0.04

Disc Medicine's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.315 + 60.547) / 735.071
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.08 mean?
Disc Medicine (IRON) has a Debt-to-Asset of 0.08 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Disc Medicine and its competitors.
Is Disc Medicine's Debt-to-Asset too high?
Disc Medicine's current Debt-to-Asset is 0.08. Overall, Disc Medicine has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Disc Medicine's Debt-to-Asset compare to CLDX and NAMS?
Disc Medicine's Debt-to-Asset of 0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Disc Medicine and its competitors. Disc Medicine's current Debt-to-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disc Medicine stock overvalued right now?
Disc Medicine (IRON) has a current Debt-to-Asset of 0.08. The current Debt-to-Asset is 0.08. Disc Medicine's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Disc Medicine (IRON), the current Debt-to-Asset is 0.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Disc Medicine Business Description

Address 321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
35GF Score

Get the complete analysis for IRON

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$68.49
Price